Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Short term Debt (2016 - 2022)

Historic Short term Debt for Pharma (IGC) over the last 11 years, with Q2 2022 value amounting to $3000.0.

  • Pharma's Short term Debt changed 0.0% to $3000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $3000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $3000.0 for FY2022, which is 9901.32% down from last year.
  • Pharma's Short term Debt amounted to $3000.0 in Q2 2022, which was down 0.0% from $3000.0 recorded in Q1 2022.
  • Over the past 5 years, Pharma's Short term Debt peaked at $304000.0 during Q1 2021, and registered a low of $3000.0 during Q2 2021.
  • For the 4-year period, Pharma's Short term Debt averaged around $78230.8, with its median value being $50000.0 (2019).
  • Per our database at Business Quant, Pharma's Short term Debt surged by 50800.0% in 2021 and then plummeted by 9901.32% in 2022.
  • Over the past 4 years, Pharma's Short term Debt (Quarter) stood at $50000.0 in 2019, then skyrocketed by 404.0% to $252000.0 in 2020, then tumbled by 98.81% to $3000.0 in 2021, then changed by 0.0% to $3000.0 in 2022.
  • Its Short term Debt was $3000.0 in Q2 2022, compared to $3000.0 in Q1 2022 and $3000.0 in Q4 2021.